Salud financiera de hoja de balance de RAPT Therapeutics
Salud financiera controles de criterios 6/6
RAPT Therapeutics tiene unos fondos propios totales de $172.8M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $199.7M y $26.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$158.86m |
| Patrimonio | US$147.04m |
| Total pasivo | US$26.29m |
| Activos totales | US$173.33m |
Actualizaciones recientes sobre salud financiera
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25Recent updates
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16Análisis de la situación financiera
Pasivos a corto plazo: RAPTLos activos a corto plazo ($187.1M) de la empresa superan a sus pasivos a corto plazo ($21.8M).
Pasivo a largo plazo: RAPTLos activos a corto plazo ($187.1M) superan a sus pasivos a largo plazo ($5.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: RAPT está libre de deudas.
Reducción de la deuda: RAPT no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: RAPT tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: RAPT dispone de suficiente liquidez para 1.5 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 20.8% cada año.